DBVT vs. BLUE, SGMO, BCAB, LIFE, OTLK, MOLN, OMGA, SCLX, CRIS, and PASG
Should you be buying DBV Technologies stock or one of its competitors? The main competitors of DBV Technologies include bluebird bio (BLUE), Sangamo Therapeutics (SGMO), BioAtla (BCAB), aTyr Pharma (LIFE), Outlook Therapeutics (OTLK), Molecular Partners (MOLN), Omega Therapeutics (OMGA), Scilex (SCLX), Curis (CRIS), and Passage Bio (PASG). These companies are all part of the "biological products, except diagnostic" industry.
DBV Technologies (NASDAQ:DBVT) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.
DBV Technologies has higher earnings, but lower revenue than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.
DBV Technologies presently has a consensus target price of $3.33, suggesting a potential upside of 471.27%. bluebird bio has a consensus target price of $5.74, suggesting a potential upside of 457.71%. Given DBV Technologies' stronger consensus rating and higher probable upside, analysts plainly believe DBV Technologies is more favorable than bluebird bio.
DBV Technologies has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, bluebird bio has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.
bluebird bio received 636 more outperform votes than DBV Technologies when rated by MarketBeat users. Likewise, 71.78% of users gave bluebird bio an outperform vote while only 57.16% of users gave DBV Technologies an outperform vote.
71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 87.4% of bluebird bio shares are owned by institutional investors. 0.7% of DBV Technologies shares are owned by company insiders. Comparatively, 2.1% of bluebird bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, DBV Technologies and DBV Technologies both had 10 articles in the media. DBV Technologies' average media sentiment score of 0.53 beat bluebird bio's score of 0.00 indicating that DBV Technologies is being referred to more favorably in the media.
bluebird bio has a net margin of -419.64% compared to DBV Technologies' net margin of -530.89%. bluebird bio's return on equity of -34.32% beat DBV Technologies' return on equity.
Summary
bluebird bio beats DBV Technologies on 10 of the 17 factors compared between the two stocks.
Get DBV Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DBVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DBV Technologies Competitors List
Related Companies and Tools
